4 papers in the library · 9 citations · publishing 2024-2026
J Affect Disord February 23, 2026 Xiaofeng Lan, Zitao Wu, Chengyu Wang et al.
Multiple peripheral inflammatory markers in adolescents with major depressive disorder treated with repeated esketamine infusions: results from a randomized controlled trial.
CNS Neuroscience & Therapeutics March 1, 2025 Zerui You, Xiaofeng Lan, Chengyu Wang et al. 1 citation
Despite the clinical benefits of ketamine in treating major depressive disorder (MDD), some patients exhibit drug resistance, and the intricate mechanisms underlying this await comprehensive explication. We used metabolomics to find biomarkers for ketamine efficacy and uncover its mechanisms of action. The study included 40 MDD patients treated with ketamine in the discovery cohort and 24...
Cell Biology and Toxicology January 10, 2025 Nan Zhou, Xiaolei Shi, Runhua Wang et al. 1 citation
Major depressive disorder (MDD) is characterized by persistent feelings of sadness and loss of interest. Ketamine has been widely used to treat MDD owing to its rapid effect in relieving depressive symptoms. Importantly, not all patients respond to ketamine treatment. Identifying sub-populations who will benefit from ketamine, as well as those who may not, prior to treatment initiation, would...
European psychiatry : the journal of the Association of European Psychiatrists April 4, 2024 Haiyan Liu, Chengyu Wang, Xiaofeng Lan et al. 7 citations
Amygdala subregion-based network dysfunction has been determined to be centrally implicated in major depressive disorder (MDD). Little is known about whether ketamine modulates amygdala subarea-related networks. We aimed to investigate the relationships between changes in the resting-state functional connectivity (RSFC) of amygdala subregions and ketamine treatment and to identify important...